Research programme: cancer immunotherapeutics - igeneon

Drug Profile

Research programme: cancer immunotherapeutics - igeneon

Alternative Names: IGN 312; Monoclonal antibodies research programme - igeneon

Latest Information Update: 05 Nov 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator igeneon Krebs-Immuntherapie Forschungs- und Entwicklungs-AG
  • Class Monoclonal antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 05 Nov 2009 Discontinued - Preclinical for Cancer in Austria (unspecified route)
  • 07 Feb 2006 Pending directorship approval, Igeneon will license IGN 312 to Celltrion in Europe and certain Asian countries, including Japan
  • 29 Mar 2005 igeneon Krebs Immuntherapie Forschungs und Entwicklungs AG has been acquired by Aphton Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top